Related Experiment Video
Updated: Mar 26, 2026
08:54
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
21.7K
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus
Shawn R Lockhart1, Annette W Fothergill2, Naureen Iqbal1
1Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Antimicrobial Agents and Chemotherapy
|January 21, 2016
Summary
The novel fungal Cyp51 inhibitor VT-1129 shows potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii. VT-1129 is more effective than fluconazole, especially against fluconazole-resistant strains.
Area of Science:
- Mycology
- Infectious Diseases
- Antifungal Drug Discovery
Background:
- Cryptococcus neoformans and Cryptococcus gattii are major fungal pathogens causing cryptococcosis.
- Emergence of antifungal resistance necessitates development of novel therapeutic agents.
- The enzyme lanosterol 14α-demethylase (Cyp51) is a validated target for antifungal drugs.
Purpose of the Study:
- To evaluate the in vitro antifungal activity of VT-1129, a novel fungal Cyp51 inhibitor.
- To compare the efficacy of VT-1129 against fluconazole in Cryptococcus species isolates.
Main Methods:
- Broth microdilution method was used to determine the minimum inhibitory concentrations (MICs).
- A large panel of Cryptococcus neoformans and Cryptococcus gattii isolates were tested.
- Geometric mean MICs were calculated and compared between VT-1129 and fluconazole.
Main Results:
- VT-1129 demonstrated potent in vitro activity against both C. neoformans and C. gattii, with low MIC50 and MIC90 values.
- The in vitro potency of VT-1129 was consistent across all genotypes of C. gattii.
- Significantly lower geometric mean MICs were observed for VT-1129 compared to fluconazole against C. neoformans, including fluconazole-resistant isolates.
Conclusions:
- VT-1129 exhibits broad-spectrum in vitro activity against clinically relevant Cryptococcus species.
- VT-1129 represents a promising therapeutic candidate for cryptococcosis, particularly in cases of fluconazole resistance.
Related Concept Videos
01:15Antifungal Agents
37
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
37
01:28Antimicrobial Effectiveness
2.0K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
2.0K